United States · Platforms & data · MarketBeat
Denali Therapeutics Targets All Eligible Hunter Disease Patients as Pipeline Milestones Near
Detailed summary
Denali Therapeutics (NASDAQ:DNLI) is targeting all eligible U.S. patients for its Hunter disease treatment AVLAYAH, while preparing data updates across a pipeline that includes treatments for Sanfilippo syndrome, Pompe disease and Alzheimer’s disease. Chief Scientific Officer Joe Lewcock said AVLAY
MarketNews shows the headline and summary published by the outlet. The full article is on the publisher's website. (www.marketbeat.com)
